In the year ended 31 December 2024, Biodexa did not generate any gross revenue
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biotech Alert: Searches spiking for these stocks today
- 3 Penny Stocks to Watch Now, 3/20/25
- Biodexa says on track to initiate Phase 3 trial in FAP next quarter
- Biodexa Pharmaceuticals Advances Phase 3 eRapa Program with FDA Approval
- Biodexa Pharmaceuticals announces outcome of a Type C meeting with FDA on eRapa